Health
Study finds some antibody therapies cannot combat new COVID variants – European Pharmaceutical Review
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against new SARS-CoV-2 variants, while other antibodies were not.
Posted: 28 January 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lillys bamlanivimab, were not.
New research suggests that new variants of the SARS-CoV-2 virus are more resistant to neutralisation with antibody therapies, including convalescent plasma and vaccinee sera. According to the authors of the paper, currently…
Continue Reading
